Freda Yang

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Liam G. Heaney, John Busby, Catherine E. Hanratty et al. · The Lancet Respiratory Medicine · 2020 · 129 citations · Full text

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

P. Jane McDowell, Sarah Diver, Freda Yang et al. · The Lancet Respiratory Medicine · 2021 · 103 citations

Asthma, Inflammation, Allergy +10

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text

Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events

Chloë I. Bloom, Freda Yang, Richard Hubbard et al. · American Journal of Respiratory and Critical Care Medicine · 2024 · 36 citations · Full text

Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry

Freda Yang, John Busby, Liam G. Heaney et al. · The Journal of Allergy and Clinical Immunology In Practice · 2021 · 29 citations · Full text